Meeder Asset Management Inc. Has $916,000 Stock Position in Ralliant Corporation $RAL

by · The Cerbat Gem

Meeder Asset Management Inc. grew its holdings in shares of Ralliant Corporation (NYSE:RAL – Free Report) by 95,122.7% during the third quarter, according to its most recent filing with the Securities and Exchange Commission. The institutional investor owned 20,949 shares of the company’s stock after purchasing an additional 20,927 shares during the quarter. Meeder Asset Management Inc.’s holdings in Ralliant were worth $916,000 as of its most recent filing with the Securities and Exchange Commission.

A number of other large investors have also recently bought and sold shares of RAL. ST Germain D J Co. Inc. bought a new position in Ralliant during the second quarter valued at about $27,000. Manchester Capital Management LLC acquired a new position in shares of Ralliant during the 2nd quarter valued at about $29,000. Evermay Wealth Management LLC bought a new position in shares of Ralliant in the 2nd quarter valued at approximately $32,000. Webster Bank N. A. acquired a new stake in Ralliant in the 3rd quarter worth approximately $31,000. Finally, SouthState Corp bought a new stake in Ralliant during the second quarter worth approximately $35,000.

Ralliant Stock Performance

NYSE:RAL opened at $52.48 on Monday. The stock’s 50-day moving average is $49.32. The company has a market cap of $5.92 billion and a P/E ratio of 41.33. The company has a debt-to-equity ratio of 0.39, a quick ratio of 1.03 and a current ratio of 1.49. Ralliant Corporation has a 52-week low of $40.70 and a 52-week high of $55.08.

Ralliant (NYSE:RAL – Get Free Report) last released its earnings results on Wednesday, November 5th. The company reported $0.60 earnings per share for the quarter, beating the consensus estimate of $0.58 by $0.02. The company had revenue of $529.10 million during the quarter, compared to the consensus estimate of $519.14 million. Ralliant has set its Q4 2025 guidance at 0.620-0.680 EPS.

Ralliant Announces Dividend

The company also recently disclosed a quarterly dividend, which was paid on Tuesday, December 23rd. Stockholders of record on Monday, December 8th were issued a dividend of $0.05 per share. This represents a $0.20 annualized dividend and a dividend yield of 0.4%. The ex-dividend date of this dividend was Monday, December 8th. Ralliant’s dividend payout ratio (DPR) is presently 15.75%.

Analyst Upgrades and Downgrades

RAL has been the topic of a number of recent analyst reports. Weiss Ratings reissued a “hold (c)” rating on shares of Ralliant in a research report on Monday, December 29th. Oppenheimer raised their target price on shares of Ralliant from $55.00 to $60.00 and gave the company an “outperform” rating in a research note on Monday, December 15th. Barclays boosted their target price on shares of Ralliant from $59.00 to $60.00 and gave the stock an “overweight” rating in a research report on Wednesday. Citigroup raised Ralliant from a “neutral” rating to a “buy” rating and raised their price target for the company from $53.00 to $61.00 in a research report on Monday, December 8th. Finally, Royal Bank Of Canada boosted their price objective on Ralliant from $45.00 to $52.00 and gave the stock a “sector perform” rating in a research report on Friday, November 7th. Six investment analysts have rated the stock with a Buy rating and six have assigned a Hold rating to the stock. Based on data from MarketBeat, the company presently has a consensus rating of “Moderate Buy” and a consensus price target of $58.00.

Get Our Latest Report on RAL

About Ralliant

(Free Report)

Ralliant, Inc (NYSE: RAL) is a medical technology company focused on enabling point-of-care cell therapy solutions in the field of regenerative medicine. The company develops and markets systems that isolate, concentrate and store adipose-derived stromal vascular fraction (SVF) cells directly from a patient’s own fat tissue, facilitating same-day, autologous treatments without the need for extensive laboratory infrastructure.

The company’s core product portfolio includes proprietary device platforms and single-use processing kits engineered to streamline the workflow for clinicians.

Featured Stories

Want to see what other hedge funds are holding RAL? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Ralliant Corporation (NYSE:RAL – Free Report).